SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[_] Definitive Additional Materials
[X] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
<PAGE>
The following is the text of an advertisement first issued by ICN
Pharmaceuticals, Inc. in the Wall Street Journal on October 13, 2000 and to
be issued subsequently in other publications:
This is ICN . . .
Innovation and Growth.
Compounded Growth 29% Vision = Results
5 Years of Record Revenues
(1,3) Revenues (BAR GRAPH) Financial Results:
1995 273M ICN's compounded five-year
1996 347M growth is our success:
1997 527M -Revenues 29%;
1998 698M -Operating income 44%
1999 747M
Compounded Growth 44% Shareholder Value Results:
4 Years of Record Operating Income Strong Stock Performance . . . (4)
(1,3) Operating Income (BAR GRAPH)
1995 47M YTD 1 Yr 5 Yr 10 Yr
--- ---- ---- -----
1996 43M 35% 101% 142% 914%
1997 64M
1998 121M (2)
1999 199M
(3) Dividends (BAR GRAPH) ICN delivered to shareholders.
1995 $0.19
1996 $0.20
1997 $0.21
1998 $0.24
1999 $0.28
1 Excludes Yugoslavia.
2 Excludes Eastern European charges, including losses incurred in
Yugoslavia in the second quarter of 1998, losses incurred in the third
quarter of 1998, related to the Russian economic crisis, and the write-off
of ICN Yugoslavia.
3 Charts not to scale.
4 Cumulative return based on the stock price as of close of business
10/6/00 excluding dividend reinvestment.
ICN stockholders are strongly advised to read the proxy statement relating
to ICN's 2000 annual meeting of stockholders when it becomes available, as
it will contain important information. Stockholders will be able to obtain
this proxy statement, any amendments to the proxy statement and other
documents filed by ICN with the Securities and Exchange Commission for free
at the Internet website maintained by the Securities and Exchange
Commission at www.sec.gov. In addition, ICN will mail the proxy statement
to each stockholder of record on the record date to be established for the
stockholders meeting. ICN will also make additional copies of the proxy
statement and any amendments to the proxy statement available for free to
ICN's stockholders. Please direct your request for the proxy statement to
Investor Relations, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa
Mesa, California 92626, telephone (714) 545-0100, extension 3104.
ICN, its executive officers and directors may be deemed to be participants
in the solicitation of proxies for ICN's 2000 annual meeting of
stockholders. Information regarding these participants is contained in the
Schedule 14A filed by ICN with the Securities and Exchange Commission on
October 6, 2000.
ICN Pharmaceuticals, Inc.
3300 Hyland Avenue, Costa Mesa, CA 92626
TEL: 800-548-5100 x2403, WEB: icnpharm.com
[Logo of ICN Pharmaceuticals, Inc.]
